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ABSTRACT
Objectives: To determine the frequency of antibodies to chromatin components in juvenile systemic lupus erythematosus 
(JSLE), and to correlate the presence of these autoantibodies with clinical manifestations and disease activity. Methods: 
Anti-chromatin (anti-CHR), anti-nucleosome core particle (anti-NCS) and anti-dsDNA antibodies were measured in 
175 individuals, including 37 patients with active JSLE and 41 with inactive disease, 47 non-lupus autoimmune disease 
patients (non-lupus AD), and 50 healthy children. An in-house ELISA was developed with purifi ed nucleosome core 
particles from calf thymus to determine IgG and IgG3 anti-NCS antibodies. Anti-CHR and anti-dsDNA antibodies were 
detected by commercial ELISA kits (INOVA). Results: Anti-NCS and anti-CHR antibodies exhibited high specifi city 
for JSLE and similar frequency in active and inactive JSLE. Anti-CHR and IgG/IgG3 anti-NCS serum levels did not 
differ between active and inactive JSLE. SLEDAI correlated with anti-dsDNA antibodies but not with antibodies to 
other chromatin components. There was association of anti-dsDNA, anti-CHR and IgG/IgG3 anti-NCS antibodies with 
proteinuria and low C4 serum levels. Anti-NCS antibodies in the absence of anti-dsDNA were observed in 14% of the 
JSLE patients. Conclusions: Our data indicate that anti-NCS and anti-CHR antibodies are relevant diagnostic markers 
for JSLE and appear to be correlated with JSLE lupus nephritis activity. IgG3 isotype anti-NCS antibodies do not seem 
to be more relevant than IgG anti-NCS antibodies as markers of disease activity or active nephritis in JSLE. 
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INTRODUCTION
Systemic lupus erythematosus (SLE) is a multi-organ au-
toimmune disease characterized by a wide range of clinical 
manifestations. SLE nephritis bears considerable morbidity 
and represents a major threat to long-term quality of life and 
survival. Renal involvement has been reported in 40%–80% of 
juvenile systemic lupus erythematosus patients (disease onset 
before 16 years old) and this high frequency contributes to the 
severity of juvenile systemic lupus erythematosus (JSLE).1 SLE 
is characterized by the presence of circulating autoantibodies 
against nuclear components (ANA).2 More than 100 different 
autoantibodies have been identifi ed in the serum of SLE patients3 
and some of these are clinically useful as diagnostic markers and 
as ancillary parameters for disease activity monitoring.4 Among 
the clinically useful SLE autoantibodies, anti-native DNA, anti- 
Sm and anti-ribosomal P protein are considered to be specifi c 
diagnostic markers but their modest sensitivity restricts their 
diagnostic performance. This scenario has endorsed the search 
for novel and more effi cient biomarkers for SLE.5 
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The nucleosome core particle is the fundamental chromatin 
unit and is composed of ~146 base pairs of DNA wrapped 
around a protein core, an octamer comprising two molecules of 
each of the histones H2A, H2B, H3 and H4. The nucleosome 
core particles are joined together by a linker DNA, which is 
associated with histone H1 located outside the nucleosome core 
particles.6 During cell apoptosis, nucleosomes are released in 
the intracellular milieu by endonuclease chromatin cleavage. 
In physiologic conditions, phagocytes engulf apoptotic cells 
and apoptotic bodies to prevent the release of cell constituents 
in the extracellular space.7 In the last 15 years, several pieces 
of evidence have suggested that the nucleosome is a major 
antigenic domain in SLE pathophysiology, and that antibodies 
to nucleosome core particles (anti-NCS/CHR) are associated 
with organ damage.8–10 Additionally, there is isolated evidence 
that IgG3 isotype anti-NCS antibodies might constitute a 
selective biologic marker of active SLE, and in particular, 
of lupus nephritis.11 Although several studies evaluated the 
diagnostic performance of anti-NCS or anti-CHR antibodies 
in adult SLE patients, there are only a few studies about these 
autoantibodies in JSLE.12–14
The aim of the present study was to investigate the diag-
nostic performance of antibodies to the chromatin antigenic 
system in JSLE as well as their associations with Systemic 
Lupus Erythematosus Disease Activity Index (SLEDAI) and 
with individual clinical manifestations of the disease, with 
emphasis on lupus nephritis.
MATERIALS AND METHODS
Patients and controls
Over a two-year period, 125 patients aged 5–18 years old 
were sequentially recruited from the outpatient clinic of the 
Department of Pediatrics at Universidade Federal de São Paulo 
and Santa Casa de Misericórdia Medical School Hospital, in 
São Paulo, Brazil. Disease distribution among patients was: 
37 children had active JSLE; 41 had inactive JSLE; 47 had 
non-lupus autoimmune diseases (non-lupus AD) comprising 
systemic sclerosis (SSc; n = 4), juvenile idiopathic arthritis 
(JIA; n = 28), dermatomyositis (DM; n = 7), and chronic 
autoimmune hepatitis (n = 8). SLE, JIA, SSc and DM were 
diagnosed according to the American College of Rheumatology 
criteria and International Autoimmune Hepatitis Group 
respectively.15–19 Clinical and laboratory information (renal, 
hematological and skin involvement, arthritis, fever, alopecia, 
mucous ulcers, chronic headache, neurological manifestations, 
vasculitis, and serositis) were obtained for each JSLE patient in 
order to determine the disease activity score using SLEDAI.20 
Inactive JSLE and active JSLE was arbitrarily defi ned as 
SLEDAI ≤ 2 and ≥ 6, respectively.21 Patients with SLEDAI 
scores 3, 4, and 5 were excluded from the study. Sera from 
50 gender and age-matched healthy children and adolescents 
were used as controls. These individuals were relatives from 
laboratory staff and otherwise healthy children referred for 
small surgical procedures. The study was approved by the 
Institutional Ethics Committee (# 1149/04).
Each participant provided 10 mL of blood for laboratory 
tests after having the informed consent signed by parents or 
legal guardians. The samples were stored at −20ºC until used. 
At the time of serum harvest, most JSLE patients were under 
treatment with immunosuppressant drugs. Intravenous cyclo-
phosphamide was used in 2.5%, pulse therapy with methyl-
prednisolone in 7.7%, oral prednisone above 0.5 mg/kg/day 
in 65.4%, azathioprine in 33.3%, methotrexate in 6.4%, and 
hidroxychloroquine in 57.7% of the JSLE patients.
Serologic analysis
Antinuclear antibodies (ANA) were detected by indirect immu-
nofl uorescence (IIF) with in-house HEp-2 cells slides accord-
ing to the standard procedure;22 anti-dsDNA antibodies were 
determined by enzyme immunoassay (INOVA Diagnostics, 
San Diego, CA), according to the manufacturer’s directions, 
and by IIF with in-house C. luciliae slides (CLIF assay) ac-
cording to standard procedure.23 Antibodies against extractable 
nuclear antigens (ENA) were detected by double immunodif-
fusion against calf spleen extract according to Ouchterlony’s 
technique.24 Anticardiolipin antibodies were determined by 
in-house enzyme immunoassay as previously described25 and 
calibrated with international APL standards (Louisville APL 
Diagnostics Inc, Doraville, GA, USA). C3 and C4 serum lev-
els were determined by radial immunodiffusion (The Binding 
Site Ltd., Birmingham, UK) according to the manufacturer’s 
directions. Two assays were used to measure antibodies 
anti-chromatin/nucleosome. Since anti-chromatin and anti-
nucleosome antibodies are normally synonymous we decided 
in this study to name the anti-chromatin commercial assay 
anti-CHR, and the in-house anti-nucleosome assay, anti-NCS.
Nucleosome core particle preparation and 
detection of antibodies to nucleosome core 
particles (NCS) and to chromatin (CHR)
The commercial kit QUANTA LiteTM Chromatin using highly 
purifi ed calf thymus chromatin without histone H1 and non-
histone proteins (INOVA Diagnostics, San Diego, CA) was 
processed according to the manufacturer’s instructions. For 
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qualitative assessment, when using the cut-off point of 20 U/mL 
suggested by the manufacturer, results were expressed as anti-
CHR-20. Alternatively, when using the cut-off point of 60 U/mL 
(moderate to strong positive sera, according to manufacturer), 
results were expressed as anti-CHR-60.
The in-house anti-NCS immunoassay was set up to detect 
IgG and IgG3 antibodies against the nucleosome core particles 
isolated from calf thymus as previously described,26,27 with 
slight modifi cations. Briefl y, 10 g of calf thymus were ground 
and homogenized in 140 mL buffer A [0.3 M sucrose, 6 mM 
MgCl2, 1.2 mM CaCl2, 10 mM NaHSO3, 10 mM Tris-HCl, and 
0.2 mM phenylmethylsulfonyl fl uoride (PMSF), pH 7.5] and 
passed through cheesecloth and miracloth. Nuclei were isolated 
by centrifugation at 3,300 g for 8 minutes at 4ºC, washed twice 
in the same buffer, pelleted and resuspended in 8 mL 15 mM 
NaCl, 15 mM 2-mercaptoethanol, 60 mM KCl, 0.5 mM sperm-
ine, 0.15 mM spermidine, pH 7.4. The volume was adjusted to 
yield a fi nal DNA concentration of ~2,500 μg/mL as judged by 
optical density at 260 nm. The nuclei suspension was digested 
for 2 minutes at 37°C with 40 IU/mg micrococcus nuclease 
(Worthington Biochemical Corp., Likewood, NJ) in the pres-
ence of 1 mM CaCl2 and the reaction was terminated by the 
addition of 2 mM EDTA. The nuclei were pelleted at 8,000 g 
for 2 minutes at 4ºC, resuspended in the original volume with 
0.2 mM EDTA pH 7.0, and then homogenized in a tight-fi tting 
Dounce homogenizer. The homogenate was centrifuged again 
for 2 minutes at 8,000 g at 4°C and the supernatant containing 
the soluble long chromatin was recovered. H1 and non-histone 
proteins were stripped by dropwise addition of ice cold 4 M 
NaCl to a fi nal concentration 0.5 M NaCl. The non-histone 
proteins and H1 were separated from the stripped chromatin 
solution by gel fi ltration in a Sepharose 4B column (Sigma 
Chemical, St. Louis, USA) previously equilibrated with 0.45 M 
NaCl, 0.2 mM EDTA and 5mM Tris-HCl, pH 7.5. The fractions 
containing the nucleosome core particles were selected accord-
ing to agarose gel electrophoresis pattern and pooled together. 
The in-house anti-NCS ELISA was based on the assay 
developed by Burlingame and Rubin.27 ELISA plates (Nunc-
MediSorpT Surface, Denmark) were coated with 200 μL/well 
purifi ed nucleosome core particles 5 μg DNA/mL in cold 
phosphate buffered saline (PBS) for 48 hours at 4°C, and 
blocked with 200 μL/well 0.1% gelatin in PBS for 2 hours 
at room temperature (RT). Patient samples (200 μL) diluted 
1:100 in 0.1% gelatin in PBS were applied to each well and 
then allowed to react for 2 hours at RT. Plates were washed 
three times with 0.05% Tween 20 in PBS (250 μL/well) and 
then incubated for 2 hours at RT with 200 μL/well horserad-
ish peroxidase (HRP) labeled mouse anti-human IgG (Sigma, 
St. Louis, USA) 1:20,000 in 0.05% Tween 20, 0.1% gelatin, 
0.1% BSA, and 0.5% fetal calf serum (FCS) in PBS or HRP-
labeled mouse anti-human IgG3 (ZYMED Laboratories, San 
Francisco, CA) 1:2,000 in the same buffer. After washing as 
before, plates received 200 μL/well peroxidase chromogenic 
substrate (10 mg o-phenylenediamine, 10 μL H2O2 in 25 mL 
0.1 M citrate buffer, pH 5.0). After incubation under shaking 
for 1 hour at RT in a dark chamber the OD was read at 492 nm 
after the addition of 50 µL/well of stop solution (1 N H2SO4). 
Serum background reactivity was checked in uncoated wells 
processed in parallel with the test wells. The cut-off value 
was determined as the mean plus three standard deviations of 
the OD values obtained with serum samples from 80 healthy 
blood donors (0.573 for IgG anti-NCS and 0.400 for IgG3 anti-
NCS). The cut-off values obtained were compatible with the 
cut-off values derived from ROC curve analysis (see results). 
Three positive and three negative control samples, obtained 
from a private laboratory certifi ed on-site by the US College 
of American Pathologists (CAP), were included in each plate.
Statistical analysis
Continuous variables were expressed as mean and standard de-
viation. Comparison between groups was performed with t-test 
(parametric variables) or Mann-Whitney test (non-parametric 
variables) for continuous variables and chi-square or Fisher’s 
exact test for categorical variables, as needed. Correlations 
were determined by Spearman’s correlation for non-parametric 
variables. All statistical analyses were performed with SPSS 
software (version 15.0 for Windows, Chicago, USA). P < 0.05 
was considered signifi cant. 
RESULTS
Demographic data
Thirty-seven patients had active JSLE (SLEDAI score ≥ 6) 
and 41 had inactive JSLE (SLEDAI score ≤ 2). There was no 
signifi cant difference in gender, age, or ethnicity among the 
groups of 37 active JSLE (29 girls, 13.2 ± 3.4 years old, 20 
Caucasian-descendants), 41 inactive JSLE (35 girls, 12.0 ± 3.0 
years old, 23 Caucasian-descendants), 47 non-lupus AD (35 
girls, 11.0 ± 3.6 years old, 26 Caucasian-descendants), and 50 
healthy controls (35 girls, 14.0 ± 4.3 years old, 22 Caucasian-
descendants) (P = 0.153, 0.054, and 0.525, respectively). 
Patients with active JSLE had lower disease duration as com-
pared to inactive JSLE (P = 0.013) (Table 1). The clinical and 
laboratory features of patients with active and inactive JSLE 
are depicted on Table 2. Active nephritis at the moment of 
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blood withdrawing, defi ned by proteinuria above 0.5 g/day, 
was identifi ed in 15 of the 37 active JSLE patients. 
Antibodies to nucleosome core particles (NCS), 
chromatin (CHR), and to native DNA (dsDNA)
Among all JSLE patients, anti-dsDNA antibodies were detected 
in 29% by ELISA and in 14% by CLIF. IgG anti-CHR-20 and 
anti-NCS antibodies were found in 40% and 23% of all JSLE 
patients, respectively. IgG3 anti-NCS antibodies were detected 
in 18% of all JSLE patients. Table 3 depicts the frequency of 
the several autoantibodies in each group as well as data about 
sensitivity, specifi city, positive predictive value and negative 
predictive value for the diagnosis of JSLE calculated against 
non-lupus AD patients and healthy children altogether. Among 
the analyzed tests, CLIF assay for anti-dsDNA antibodies was 
the least sensitive and presented the highest specifi city and 
positive predictive value. The ELISA assays for anti-dsDNA, 
anti-CHR-60, and IgG anti-NCS had equivalent performance 
in all diagnostic parameters. The anti-CHR-20 assay presented 
higher sensitivity but lower specifi city and positive predictive 
value as compared to the three former ELISA assays. There 
was considerable heterogeneity among JSLE sera with respect 
to ELISA OD values in the anti-dsDNA, anti-CHR and anti-
NCS antibody assays (Figure 1). Patients with JSLE presented 
signifi cantly higher levels of antibodies to chromatin compo-
nents than those with non-lupus AD and healthy individuals 
(P < 0.01). ANA-HEp-2 and anti-ENA positive tests were 
observed, respectively, in 92% and 32% active JSLE, 90% and 
27% inactive JSLE, 36% and 0% non-lupus AD patients, and 
2% and 0% healthy children. Homogeneous and fi ne speckled 
were the most frequent ANA-HEp-2 patterns found in JSLE 
sera positive for any tested chromatin components.
Several parameters of disease activity showed correlation 
with antibodies to chromatin components. Anti-dsDNA anti-
bodies (CLIF assay) were more frequent in patients with active 
JSLE (SLEDAI ≥ 6) as compared to those with inactive disease 
(SLEDAI ≤ 2) (24% vs. 5%, P < 0.001). In addition, SLEDAI 
Table 1
Demographic data of patients with active JSLE, inactive JSLE, non-lupus AD, and healthy controls
Active JSLE (n = 37) Inactive JSLE (n = 41) Non-lupus AD (n = 47) Healthy controls (n = 50) P 
Gender (F/M) 31/6 36/5 35/12 35/15 0.153a
Age (years) 13.2 ± 3.4 13.2 ± 3.0 11 ± 3.6 11.5 ± 4.3 0.054a
Disease duration (months) 24 ± 23.4 41.8 ± 30.4 nd nd 0.013b
Ethnicity (C/NC) 20/17 24/17 26/21 22/28 0.525a
Mean and standard deviation. Chi-square P value: acomparison of all groups; bComparison between active and inactive JSLE patients.
F: female; M: male; C: Caucasian; NC: non Caucasian; JSLE: juvenile systemic lupus erythematosus; AD: autoimmune disease.
Table 2
Clinical and laboratory features of patients with active JSLE, inactive JSLE, non-lupus AD, and healthy controls
Active JSLE % (n = 37) Inactive JSLE % (n = 41) Non-lupus AD % (n = 47) Healthy controls % (n = 50)
Renal involvement 84% (31) None nd nd
Skin involvement 22% (8) None nd nd
Arthritis 19% (7) None nd nd
Hematological involvement 13% (5) 10% (4) nd nd
Fever 11% (4) None nd nd
Alopecia 11% (4) None nd nd
Mucous ulcers 8% (3) None nd nd
Chronic headache 8% (3) None nd nd
Neurologic manifestations 5% (2) None nd nd
Vasculitis 5% (2) None nd nd
Serositis 3% (1) None nd nd
nd: not determined; JSLE: juvenile systemic lupus erythematosus; AD: autoimmune disease.
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Table 3
Positivity, sensitivity, specifi city, positive predictive value and negative predictive value of different autoantibody assays for the 
diagnosis of JSLE in comparison with patients with non-lupus AD and healthy controls altogether
Autoantibody assay positivity (%)
CHR-20 CHR-60 NCS IgG NCS IgG3 dsDNACLIF
dsDNA
ELISA
Active JSLE (n = 37) 43% 27% 27% 22% 24% 38%
Inactive JSLE (n = 41) 36% 22% 19% 15% 5% 22%
Non-lupus AD (n = 47) 11% 4% 2% 4% 0% 6%
Healthy controls (n = 50) 0% 0% 2% 2% 0% 0%
Diagnostic parameters*
Sensitivity 40% 24% 23% 18% 11% 27%
Speciﬁ city 96% 98% 98% 95% 100% 97%
PPV 88% 90% 90% 74% 100% 87%
NPV 66% 62% 61% 58% 58% 62%
*Diagnostic parameters were calculated for the diagnosis of JSLE against non-lupus AD patients and healthy children altogether.
PPV: positive predictive value; NPV: negative predictive value; JSLE: juvenile systemic lupus erythematosus; AD: autoimmune disease; CHR-20: commercial anti-chromatin antibody assay with cut-off at 20 
U/mL; CHR-60: commercial anti-chromatin antibody assay with cut-off at 60 U/mL; NCS-IgG: in-house anti-nucleosome antibody assay for total IgG antibodies; NCS-IgG3: in-house anti-nucleosome antibody 
assay for IgG3 antibodies; CLIF: anti-dsDNA antibody assay based on indirect immunoﬂ uorescence on C. luciliae; ELISA: Enzyme-Linked Immunoabsorbent Assay.
correlated with ELISA anti-dsDNA antibody levels (r = 0.235; 
P = 0.038) but not with antibody levels to anti-CHR and anti-NCS. 
Patients with active JSLE did not differ signifi cantly from those 
with inactive JSLE with respect to the frequency and O.D. levels of an-
ti-dsDNA (424.8 ± 540.9 UI/mL vs. 208.2 ± 202.9 UI/mL; P = 0.124), 
anti-CHR-20 (56.3 ± 71.8 U/mL vs. 35.4 ± 43.7 U/mL, P = 0.537), 
IgG anti-NCS (0.589 ± 0.528 vs. 0.429 ± 0.336; P = 0.432), and 
IgG3 anti-NCS (0.536 ± 0.810 vs. 0.343 ± 0.442; P = 0.422). There 
was a signifi cantly higher frequency of proteinuria in patients with 
antibodies to any of the tested chromatin components versus those 
Figure 1
Distribution of JSLE pa-
tients, non-lupus AD patients 
and healthy controls accord-
ing to ELISA serum levels 
of antibodies to NCS, CHR 
and dsDNA. Dashed lines 
correspond to the cut-off 
threshold for each assay (for 
the anti-CHR assay there 
were cut-off levels at 20 U 
and 60 U). 
Anti-CHR: commercial anti-chro-
matin antibody assay (with cut-off 
at 20 U/mL); IgG anti-NCS: in-
house anti-nucleosome antibody 
assay for total IgG antibodies; 
IgG3 anti-NCS: in-house anti-
nucleosome antibody assay for IgG3 
antibodies; anti-dsDNA: commercial 
anti-DNA double helix antibody 
assay; ELISA: enzyme-linked im-
munoabsorbent assay.
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without them (Table 4). Correspondingly, the levels of autoanti-
bodies were signifi cantly higher in patients with proteinuria as 
compared to those without proteinuria for ELISA anti-dsDNA 
(691.1 ± 730.4 vs. 220.4 ± 217.6, P = 0.049) and IgG anti-NCS 
antibodies (0.814 ± 0.598 vs. 0.431 ± 0.365, P = 0.019). There 
was also a similar trend for anti-CHR antibodies (95.5 ± 93.1 
vs. 33.3 ± 40.6, P = 0.093) but not for IgG3 anti-NCS antibodies 
(0.811 ± 1.03 vs. 0.340 ± 0.485, P = 0.700). There was association 
between decreased C3 levels and the frequency of anti-CHR-20 
positive assay. Among JSLE patients with decreased C4 levels 
there was higher frequency of positive assays to dsDNA (ELISA), 
CHR-20, IgG NCS and IgG3 NCS (Table 4). Antibodies to iso-
lated or combined extractable nuclear antigens were observed in 
23 JSLE patients (13 anti-SS-A/Ro, four anti-SS-B/La, six anti-
Sm, and 14 anti-U1-RNP) and there was no association with the 
presence of antibodies to chromatin components. Only seven of 
the 78 JSLE patients had moderate levels of anti-cardiolipin anti-
bodies [two IgG (2.5%) and fi ve IgM (6.4%)] and no association 
was observed between reactivity to cardiolipin and presence of 
antibodies to chromatin components. Other clinical manifestations 
were equally frequent in JSLE patients with and without any of 
the tested antibodies to chromatin components (data not shown).
As depicted on Figure 2 there was good agreement 
between the ELISA assays for anti-dsDNA and anti-CHR 
antibodies (85% and 87% for CHR-20 and CHR-60, respec-
tively), between anti-dsDNA and IgG anti-NCS antibodies 
(86%), and between IgG anti-NCS and anti-CHR antibodies 
(78% and 91% for CHR-20 and CHR-60, respectively). In 
fact, we found a great similarity between the in-house anti-
NCS assay and the commercial anti-CHR assay when it was 
analyzed using 60 U/mL as cut-off value (anti-CHR-60). 
Table 4
Distribution of 78 JSLE patients according to the presence of autoantibodies to chromatin components and relevant laboratory 
parameters
Laboratory parameter
Autoantibodies
dsDNA CLIF
n = 11
dsDNA ELISA
n = 23
CHR-20
n = 33
IgG NCS
n = 18
IgG3 NCS
n = 14
Proteinuria > 0.5 g/24 h 6 (54.5%)* 9 (39.1%)* 11 (33.3%)* 7 (38.9%)* 6 (42.9%)*
Proteinuria < 0.5 g/24 h 5 (45.4%) 14 (60.9%) 22 (66.7%) 11 (61.1%) 8 (57.1%)
Decreased C3 3 (27.3%) 8 (34.8%) 13 (39.4%)* 7 (38.9%) 6 (42.9%)
Normal C3 8 (72.7%) 15 (65.2%) 20 (60.6%) 11 (61.1%) 8 (57.1%)
Decreased C4 4 (36.4%) 10 (43.5%)* 15 (45.5%)* 9 (50%)* 8 (57.1%)*
Normal C4 7 (63.6%) 13 (56.5%) 18 (54.5%) 9 (50%) 6 (42.9%)
* P < 0.05 (P values refer to Chi-square test comparing the presence/absence of each autoantibody with the presence/absence of the analyzed parameter).
CHR-20: commercial anti-chromatin antibody assay with cut-off at 20 U/mL; IgG NCS: in-house anti-nucleosome antibody assay for total IgG antibodies; IgG3 NCS: in-house anti-nucleosome antibody assay 
for IgG3 antibodies; CLIF: anti-dsDNA antibody assay based on indirect immunoﬂ uorescence on C. luciliae; ELISA: Enzyme-Linked Immunoabsorbent Assay.
Figure 2
Concordance between ELISA assays for anti-NCS, anti-CHR-20, 
anti-CHR-60, and anti-dsDNA antibodies in JSLE patients. 
Anti-CHR-20 and anti-CHR-60 refer to the ELISA anti-CHR 
assay with cut-off points at 20 U/mL and 60 U/mL, respectively. 
CHR-20: commercial anti-chromatin antibody assay with cut-off at 20 U/mL; 
CHR-60: commercial anti-chromatin antibody assay with cut-off at 60 U/mL; 
IgG anti-NCS: in-house anti-nucleosome antibody assay for total IgG anti-
bodies; IgG3 anti-NCS: in-house anti-nucleosome antibody assay for IgG3 
antibodies; anti-dsDNA: commercial anti-DNA double helix antibody assay; 
ELISA: enzyme-linked immunoabsorbent assay.
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Additionally, the agreement rate between IgG anti-NCS 
and IgG3 anti-NCS antibodies was 89%. The disagreement 
rate between the same pairs of tests ranged from 9%–21%. 
In particular, ELISA for anti-dsDNA and ELISAs for anti-
NCS or anti-CHR showed disagreement rates around 15%. 
Regarding the 23 anti-dsDNA ELISA positive patients, 22 
were also anti-CHR-20 positive.
DISCUSSION
Previous studies have addressed the analysis of autoanti-
bodies against chromatin components in SLE and related 
diseases; however, few surveys have addressed anti-NCS 
antibodies in JSLE. In the present study we have observed a 
considerable variation in the diagnostic performance of the 
tests for diverse antibodies against chromatin components 
in JSLE. The traditional CLIF anti-dsDNA was the most 
specifi c and least sensitive test. The ELISA anti-dsDNA 
and the anti-CHR-20 were the most sensitive tests, though 
slightly less specifi c. Although SLEDAI correlated only with 
anti-dsDNA antibodies, there was association between several 
of the tested autoantibodies to chromatin components and 
parameters indicative of disease activity, such as proteinuria 
and low complement levels. 
Nucleosome core particles are the fundamental units of 
chromatin and a normal product of cell apoptosis. Apoptosis 
defects are well known to be associated with certain animal 
models of lupus, and have also been discussed in connection 
with human SLE.28–31 Recent evidence obtained in murine mod-
els of SLE suggests that nucleosome core particles are a pref-
erential target for lupus autoantibodies and they are accepted 
as genuine autoantigens triggering the production of antibodies 
against the nucleosome core particles themselves, dsDNA and 
histones.32–34 According to recent literature data, the presence 
of glomerular extracellular nucleosomes derived, for instance, 
from apoptotic cells is a pre-requisite for the binding of anti-
chromatin antibodies to the glomeruli and may be involved in 
nephritic processes.33,34 Since humoral autoimmune response 
is accepted to be antigen-driven,2 a comprehensive analysis 
of autoantibodies against individual components of a supra-
molecular complex is justifi ed. In addition, technical details in 
the preparation of the antigenic substrate may be determinant 
in preserving fastidious non-linear epitopes. With respect to 
the chromatin system, this is crucial due to the delicate and 
complex interaction of native DNA and several histone and 
non-histone proteins. Therefore, each methodological platform 
favors the exposure of an unique set of epitopes and this may 
infl uence considerably the clinical signifi cance of these tests.35 
One widely accepted method for nucleosome core particle 
purifi cation consists in the solubilization of native chromatin 
by microccocal nuclease digestion and removal of H1 his-
tone and other proteins by 0.5 M NaCl extraction at neutral 
pH. Most commercial anti-NCS/chromatin kits use poly or 
mononucleosomes extracted from calf thymus chromatin as 
antigenic substrate. The present study utilized both in-house 
and commercial enzyme immunoassays. The anti-chromatin 
antibody commercial kit (anti-CHR) (INOVA Diagnostics, San 
Diego, CA) and the in-house anti-nucleosome core particle 
immunoassay (anti-NCS) used chromatin-derived antigenic 
substrates, both isolated and purifi ed from calf thymus and 
devoid of H1 histone and non-histone proteins. In addition, 
antibodies to dsDNA were determined by an ELISA com-
mercial kit and by indirect immunofl uorescence on Crithidia 
luciliae (CLIF). The performance variability of the several 
assays in the present series of patients is probably due to the 
cumulative effect of the differences in the epitope panel offered 
by the different antigenic substrates and the heterogeneous 
biochemical assay conditions of the different tests. In fact, 
the present study did not aim to compare the various tests but 
rather to explore the variability in the reactivity of JSLE sera 
against different epitope panels in assays targeting apparently 
related autoantigens.
The present study confi rmed the high specifi city of anti-
nucleosome/anti-chromatin antibodies in JSLE (anti-CHR-20, 
96% and anti-NCS, 98%) when compared with children with 
non-lupus AD and healthy children. This observation is in 
agreement with the diagnostic specifi city of anti-nucleosome/
anti-chromatin antibodies for adult lupus (mean 95%; range 
85%–98.8%). The sensitivity of the various tests for the dif-
ferent autoantibodies against chromatin components was rela-
tively low (11%–40%) when compared to the literature data 
on adult SLE.11,36–45 This may be related to specifi c features of 
JSLE and to the ethnic makeup of the studied sample or to the 
fact that most JSLE patients were under immunosuppressive 
therapy at the moment of serum harvest. In the present study 
22 of 23 (96%) anti-dsDNA ELISA positive samples were also 
anti-CHR-20 positive. This fi nding is consistent with the con-
cept that most of the anti-dsDNA antibodies in SLE patients are 
a subset of antibodies directed against chromatin.40 However, 
14% JSLE patients were reactive in the anti-CHR-20 assay but 
not in the dsDNA ELISA assay. Conversely, 1% of the JSLE 
samples were anti-dsDNA ELISA positive but anti-CHR-20 
negative. On the other hand, 15 of 23 (65%) anti-dsDNA 
ELISA positive samples were also positive in the IgG anti-NCS 
and anti-CHR-60 assays, and 4% of the JSLE patients were 
negative in these assays. Such dissociation has been reported 
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previously13,38,40,42,43,46–48 and indicates that these autoantibody 
systems have complementary roles in the diagnosis of SLE. 
This may have an impact in clinical practice inasmuch as the 
demonstration of anti-NCS antibodies in the absence of other 
autoantibodies may be particularly helpful in patients with few 
clinical manifestations (e.g. < 3 classifi cation criteria). In these 
cases, early therapy may be helpful.
The present data confi rm the importance of defi ning the 
cut-off value according to the studied population in order to 
determine the diagnostic accuracy of the various immunoen-
zyme assays in different ethnic and social frameworks. Using 
the cut-off recommended by the manufacturer in our sample, 
the commercial anti-chromatin kit (INOVA) display consider-
ably less specifi city. 
Disease activity, as measured by SLEDAI, was associated 
with the presence of anti-dsDNA (CLIF assay) and correlated 
with the serum levels of ELISA anti-dsDNA, but was not as-
sociated with any of the other tested assays. However, the low 
correlation level (r = 0.235) suggests that this parameter should 
be used with caution in the clinical practice. Interestingly, how-
ever, the presence of antibodies against chromatin components 
was largely associated in the literature with markers of active 
lupus nephritis. Several studies have previously demonstrated 
an association of anti-nucleosome antibodies and disease activ-
ity or active nephritis in SLE11,13,14,35,38,40,43,48 It has been also 
pointed that anti-nucleosome antibodies are highly correlated 
with renal failure and progression to kidney transplantation 
in SLE.49 The present study confi rmed such association also 
for JSLE and further extended the observation to several au-
toantibody specifi cities within the supra-molecular chromatin 
system. Despite the wide dispersion of the serum levels of these 
autoantibodies in patients with active and inactive disease, they 
were associated with markers of active nephritis. This suggests 
that there may be an intra-individual association of disease 
activity with anti-nucleosome and anti-dsDNA antibody serum 
levels. Therefore, prospective longitudinal studies are war-
ranted in order to further explore this possibility.
The behavior of anti-nucleosome antibodies in adult 
lupus has been analyzed according to the antibody isotype 
(IgG and IgM classes and IgG subclasses) by Amoura et al.11 
Interestingly, IgG3 anti-NCS antibodies were present in high 
levels only in active SLE patients, predominantly in active 
lupus nephritis. When testing for IgG3 anti-NCS antibodies 
in JSLE we did confi rm that IgG3 anti-NCS antibodies were 
associated with markers of active lupus nephritis such as 
proteinuria and low C4 serum level. There was a diagnostic 
sensitivity of 18% and specifi city of 95% for JSLE diagnosis. 
However, the frequency of IgG3 anti-NCS was similar in 
children with active and inactive JSLE and IgG3 anti-NCS 
serum levels did not correlate with SLEDAI. In summary, 
this is the fi rst report on JSLE regarding a comprehensive 
survey of autoantibodies against several autoantigens of the 
chromatin complex, including IgG3 anti-NCS antibodies. We 
have found high specifi city and moderate sensitivity of these 
antibodies for the diagnosis of JSLE, signaling them as help-
ful tools in the differential diagnosis of JSLE among systemic 
autoimmune diseases. There was a moderate disagreement 
rate between anti-NCS/chromatin and anti-dsDNA antibod-
ies, indicating that these are complementary autoantibodies 
for lupus diagnosis. The association of anti-NCS/chromatin 
antibodies with proteinuria and low C4 levels suggests a pos-
sible role for these antibodies as markers of lupus nephritis 
activity. Further longitudinal studies are warranted to defi ne 
the clinical utility of anti-NCS/chromatin antibodies in the 
monitoring of JSLE activity.
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